Poster#  

Presenting Author

Abstract Title

Category

P-01

Olanrewaju Akande

Validation of a novel microfluidic device as an early-stage research training tool

Academic

P-02

Nadia Alamri

Fusion of extracellular matrix binder motifs to GMCSF for localized cancerimmunotherapy

Academic

P-03

Soumendranath Bhakat

Generalizable Protein Dynamics in Kinases: Physics is the key

Trainee

P-04

Julie Conkright-Fincham

Adapting Lumit p-ERK assay to high-throughput screening using Novartis Chemogenetic LMW library

Commercial

P-05

Joseph DeCorte

GrowTAC: protein-context aware optimization of PROTAC linkers

Trainee

P-06

Umesh Desai

A Synthetic, Allosteric Inhibitor of Human Factor XIa for Lung Cancer Associated Thrombosis

Academic

P-07

Sharanya Duvvuri

Pharmacological Evaluation of novel HBV RNase H Inhibitors

Trainee

P-08

Heather Fears

MegaUni: A Scalable Platform for AI-Powered Compound Screening

Commercial

P-09

Anthony Ferranti

Investigating the mGlu7/8 Heterodimer as a Novel Drug Target for Neurodevelopmental Disorders Associated with Hippocampal Dysfunction

Trainee

P-10

Tomas Friman

Employing CETSA in Primary Screening for p53 Binders

Commercial

P-11

Khalid Garman

Intersectional high-throughput screening uncovers a synergistic drug combination for a rare and lethal skin cancer

Trainee

P-12

Niki Harris

Modulation of metabotropic glutamate receptor 7 (mGlu7) as a novel mechanism to correct NMDAR antagonist-induced cognitive impairments: implications for schizophrenia

Trainee

P-13

Md. Zahid Hossain

Neuro-Informed Algorithms: Accelerating CNS Drug Discovery with Predictive AI

Academic

P-14

Meixiang Huang

Dendrimer-Conjugated Propofol Enables Non-Sedating Neuroinflammation Therapy With >30-Fold Therapeutic Index Gain

Trainee

P-15

Meixiang Huang

Next-Generation nSMase2 Inhibitor Blocks Tau Propagation in an Alzheimer’s Model

Trainee

P-16

Genevieve Hunn

Investigating dysregulated microRNAs in Rett syndrome that regulate the GRM7 3’UTR

Trainee

P-17

Wei Li

Discovery of a potent and highly brain-penetrable anti-mitotic agent as a potential new treatment for breast cancer brain metastasis

Academic

P-18

Wei Li

Advancing Drug Discovery Through DNA-Encoded Library Technologies: Innovations, Applications, and Future Directions

Commercial

P-19

Mengchu Li

Identification of a Drug-like Negative Allosteric Modulator of the Mu-Opioid Receptor (Mu-NAM)

Trainee

P-20

Natalia Martinez

Integrating Machine Learning and High Throughput Screening to identify chemical probe candidates for Aldehyde Dehydrogenases

Academic

P-21

Marvin Meyers

Discovery of Potent Therapeutics for Treatment of Cryptosporidiosis

Academic

P-22

Sorrayut Mongkoltipparat

Proteomics-Based LC–MRM–MS/MS Platform for Kinetic and Selectivity Profiling of Covalent Inhibitors

Academic

P-23

Omar Moukha-Chafiq

Novel Pyrrolopyrimidine Nucleoside Analogs as Anti-Hepatitis B Virus Agents

Academic

P-24

Harrison Parent

Investigating Metabotropic Glutamate Receptor 7 as a Drug Target for Cognitive Phenotypes in Neurofibromatosis Type 1

Trainee

P-25

Barnali Paul

Structure guided efficacy modulation to design opioid sparing agents

Academic

P-26

ARGHYA POLLEY

Allosteric modulation of mu opioid receptor

Academic

P-27

Thomas Prisinzano

Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression

Academic

P-28

Nokomis Ramos-Gonzalez

Modulating efficacy and functional selectivity of the kappa opioid receptor

Trainee

P-29

Mark Rutherford

Development of the first subtype selective AMPA-type glutamate receptor pore blocker to halt glutamate excitotoxicity: Calcium-permeable AMPA receptors in noise-induced hearing loss and ischemic stroke.

Academic

P-30

Matthew Shaffer

Early Preclinical CMC Development of SAgA-T1D: A Protein-Polysaccharide Conjugate to Treat Type 1 Diabetes

Academic

P-31

Yu Su

Orally Bioavailable GCPII Inhibitor Promotes Remyelination After Peripheral Nerve Injury

Trainee

P-32

Razia Tajwar

Truncated variant of Hepatitis B virus polymerase catalyzes cryptic and e RNA-dependent protein priming reactions

Academic

P-33

Steve Valentino

Miniaturized Biophysical Screening of Cereblon with Dianthus uHTS and Echo Acoustic Liquid Handling

Commercial

P-34

Balazs R. Varga

Structure-guided partial 5-HT2A agonism achieves antinociception with reduced central liabilities

Trainee

P-35

Sestina Ventresca Wilburn

Enhancement of cAMP levels by α-MSH, ACTH, and the API from Purified Cortrophin® Gel at Five Melanocortin Receptors

Trainee

P-36

Holly Walden

Biological and pharmacological characteristics of a novel HBV ribonuclease H inhibitor class

Trainee

P-37

Kristen Wang

Designing antigen-based therapeutics to modulate Type 1 Diabetes-associated autoimmune cell signaling

Academic

P-38

Emma Webb

Protease-activated Receptor 4 (PAR4) is an Essential Mediator of Inflammation

Trainee

P-39

Noah Yocum

Structure-Guided Optimization of Imidazopyridine Amine Inhibitors of the Epigenetically Dysregulated Nutrient Carrier SLC1A1/EAAT3 for Renal Cell Carcinoma

Academic

P-40

Puhan Zhao

Exploiting Molecular Dynamics-Derived 5HT3A Receptor Conformational Ensembles for Structure-Based Virtual Screening

Trainee

P-41

Bin Zhao

Fragment-Based NMR Screening to Disrupt the YAP–TEAD Interaction

Academic

P-42

Haoran Zhu

Structural Based Discovery on Kappa Opioid Receptor Agonists

Trainee

P-43

Silviya Zustiak

Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels

Academic

P-44

Maaike Everts

Making Translation Work: TRxA - A Real-World Solution for Academic Research

Academic

P-45

Christopher Goins

The Center for Therapeutics Discovery at Cleveland Clinic Research

Academic

P-46

Charles Hart

Applications of AI in Early-Stage Drug Discovery and Chemical Biology at UCSF’s Small Molecule Discovery Center

Academic

P-47

Ma. Xenia Ilagan

Translating Discovery into Therapeutics: The WashU Center for Drug Discovery

Academic

P-48

Chafiq Hamdouchi

Advancing Oncology Innovation through the Indiana University Simon Comprehensive Cancer Center's Cancer Drug Discovery & Development Accelerator (CD3A)

Academic

P-49

Christopher Moth

Meiler Lab: Transatlantic computational methods development for Drug Discovery

Academic

P-50

John Tavis

Saint Louis University Institute for Drug and Biotherapeutic Innovation

Academic

P-51

Peter Toogood

Identification of Selective Pyruvate Dehydrogenase Kinase 1 (PDHK1) Inhibitors by Virtual Screening

Academic

P-52

Peter Toogood

Introduction to Michigan Drug Discovery

Academic

P-53

Henry Valle

Unlocking New Insights Into Targeting LRRK2 for Parkinson's Disease: Advancing Drug Discovery with the CAS Biofinder Discovery Platform

Commercial